Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a ...

US biotech Cartesian Therapeutics has reported that patients with generalized myasthenia gravis (gMG) continued to experience ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles ...

The randomized control period of the MINT trial has completed, and these newest data describe outcomes among patients who ...

Treatment with inebilizumab is significantly effective and safe for patients with AChR+ or MuSK+ generalized myasthenia ...

On (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of ...

Cartesian reports 12-month data for Descartes-08 in myasthenia gravis; Phase 3 AURORA trial expected to begin in Q2 2025.

J&J exhibited additional findings from the Vivacity-MG3 study, displaying that nipocalimab met its key secondary endpoint.

Johnson & Johnson (NYSE:JNJ) announced compelling results from its Phase 3 Vivacity-MG3 study on nipocalimab, showing promising efficacy and safety in treating generalized myasthenia gravis, which ...

MG-ADL (Myasthenia Gravis - Activities of Daily Living) provides a rapid clinical assessment of the patient's recall of symptoms impacting activities of daily living, with a total score range of 0 to ...

On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and ...

Interim results from the ME&MGopen study demonstrate strong adherence, high usability, and meaningful clinical associations in myasthenia ...